Comparative Pharmacology
Head-to-head clinical analysis: TRIPROLIDINE HYDROCHLORIDE PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPROLIDINE HYDROCHLORIDE PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus XYZAL.
TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triprolidine is a first-generation antihistamine that competes with histamine for H1-receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a nasal decongestant via alpha-adrenergic receptor activation, causing vasoconstriction. Codeine is an opioid agonist at mu-opioid receptors, producing antitussive effects by suppressing the cough center in the medulla.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
Each 5 mL oral solution contains triprolidine HCl 1.25 mg, pseudoephedrine HCl 30 mg, and codeine phosphate 10 mg. Adult dose: 10 mL (2 teaspoonfuls) every 4 to 6 hours, not to exceed 40 mL in 24 hours.
5 mg orally once daily in the evening.
None Documented
None Documented
Triprolidine: 3-6 hours (increased in elderly). Pseudoephedrine: 5-8 hours (prolonged with alkaline urine; up to 16 hours at pH 8). Codeine: 2.5-3.5 hours (terminal half-life; morphine metabolite ~2-3 hours).
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Triprolidine: predominantly renal (85% as metabolites, <5% unchanged). Pseudoephedrine: renal (70-90% unchanged, dependent on urine pH). Codeine: renal (86% total, 5-15% unchanged, rest as conjugates and metabolites including morphine).
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category A/B
Category C
Antihistamine
Antihistamine